SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77648.61
882.69 (1.15%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Nectar Lifesciences Ltd.	Q V PT	199 Small Cap	10.28 (0.49%)	N/A	0.34	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Health X Platform Ltd.	Q V PT	968 Small Cap	306.30 (0.71%)	N/A	3.57	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Indoco Remedies Ltd.	Q V+ PT	2,105 Small Cap	229.25 (0.50%)	20.11	1.92	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Unichem Laboratories Ltd.	Q V PT	3,763 Small Cap	532.05 (-0.45%)	23.67	1.44	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Solara Active Pharma Sciences Ltd.	Q V PT	2,446 Small Cap	504.80 (-0.43%)	N/A	1.92	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Suraksha Diagnostic Ltd.	Q V PT	1,297 Small Cap	248.35 (-0.30%)	40.31	5.3	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Jubilant Pharmova Ltd.	Q V+ PT	15,366 Small Cap	977.50 (1.33%)	772.15	6.65	-24.99	-38.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Dishman Carbogen Amcis Ltd.	Q V+ PT	2,857 Small Cap	186.20 (2.20%)	29.31	0.43	5.82	-33.01	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Biocon Ltd.	Q V PT	70,452 Mid Cap	431.50 (-0.19%)	1893.86	2.58	2.96	-18.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Shilpa Medicare Ltd.	Q V+ PT	11,839 Small Cap	606 (0.12%)	48.65	4.57	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Alembic Pharmaceuticals Ltd.	Q V+ PT	16,085 Small Cap	807.80 (-1.28%)	23.84	2.83	6.37	-8.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Sanofi India Ltd.	Q V PT	7,743 Small Cap	3,392.80 (0.91%)	24.99	9.93	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Piramal Pharma Ltd.	Q V PT	25,748 Small Cap	195.15 (0.90%)	36.78	3.19	10.23	-6.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Granules India Ltd.	Q V+ PT	20,957 Small Cap	845 (-0.09%)	52.01	5.11	2.07	-5.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Cohance Lifesciences Ltd.	Q V+ PT	16,299 Small Cap	429.20 (0.75%)	90.94	4.17	7.51	-3.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Laurus Labs Ltd.	Q V+ PT	94,987 Mid Cap	1,779.90 (1.25%)	86.88	16.84	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Tarsons Products Ltd.	Q V PT	1,655 Small Cap	320.20 (2.94%)	73.04	2.45	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Hikal Ltd.	Q V+ PT	2,676 Small Cap	220.60 (1.64%)	N/A	2.23	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Strides Pharma Science Ltd.	Q V+ PT	9,604 Small Cap	1,052 (0.96%)	52.3	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Aurobindo Pharma Ltd.	Q V+ PT	89,212 Mid Cap	1,591.90 (2.67%)	36.94	3.93	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Fermenta Biotech Ltd.	Q V PT	1,343 Small Cap	448.50 (-1.70%)	20.89	3.2	3.85	-0.38	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Onesource Specialty Pharma Ltd.	Q V PT	19,809 Small Cap	1,739.85 (0.72%)	415.98	3.3	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Aarti Pharmalabs Ltd.	Q V+ PT	6,129 Small Cap	683.65 (1.15%)	34.78	3.09	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Dr. Agarwals Health Care Ltd.	Q V PT	15,602 Small Cap	490 (-0.44%)	117.14	7.7	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	4,315 Small Cap	147.50 (0.34%)	31.35	2.4	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,783 Small Cap	214.75 (2.75%)	4.37	5.09	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Panacea Biotec Ltd.	Q V+ PT	2,540 Small Cap	422 (1.75%)	N/A	8.91	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Nephrocare Health Services Ltd.	Q V+ PT	6,927 Small Cap	699.25 (1.51%)	N/A	7.27	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Fischer Medical Ventures Ltd.	Q V PT	2,411 Small Cap	35.92 (-2.50%)	N/A	7.72	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Gujarat Kidney And Super Speciality Ltd.	Q V PT	1,001 Small Cap	127.05 (0.04%)	101.13	4.06	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Artemis MedicareServ	300.90	8.55%
Suven Life Sciences	309.25	5.10%
Divis Laboratories	7,772.65	4.75%
SMS Pharmaceuticals	397.50	4.36%
Dr. Lal Pathlabs	1,880.95	4.14%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Hester Biosciences	2,456.65	-2.71%
Fischer Medical	35.92	-2.50%
Fermenta Biotech	448.50	-1.70%
Alembic Pharma	807.80	-1.28%
3B Blackbio Dx	1,280.50	-1.21%

News about Top Pharma Companies in India

Jul, 2026

Biocon informs about company statement

Biocon has informed that it enclosed Company Statement with respect to ‘Biocon Receives Health Canada Approval for Yesintek® (ustekinumab) Autoinjector Pen’. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Indoco Remedies - Quaterly Results

The total revenue for the quarter ended June 2026 remained nearly unchanged at Rs. 4089.70 millions.The Total Profit for the quarter ended June 2026 of Rs. 823.20 millions grew from Rs.-280.70 millionsOP of the company witnessed a marginal growth to 466.80 millions from 204.00 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	4089.70	3943.10	3.72	4089.70	3943.10	3.72	16860.70	15181.90	11.06
Other Income	44.70	55.80	-19.89	44.70	55.80	-19.89	296.40	184.80	60.39
PBIDT	466.80	204.00	128.82	466.80	204.00	128.82	1867.90	1465.20	27.48
Interest	227.50	236.10	-3.64	227.50	236.10	-3.64	885.00	566.30	56.28
PBDT	1212.70	-32.10	-3877.88	1212.70	-32.10	-3877.88	954.30	908.80	5.01
Depreciation	280.50	252.00	11.31	280.50	252.00	11.31	1069.00	982.50	8.80
PBT	932.20	-284.10	-428.12	932.20	-284.10	-428.12	-114.70	-73.70	55.63
TAX	109.00	-3.40	-3305.88	109.00	-3.40	-3305.88	-58.10	13.60	-527.21
Deferred Tax	3.40	-3.40	-200.00	3.40	-3.40	-200.00	-87.30	13.60	-741.91
PAT	823.20	-280.70	-393.27	823.20	-280.70	-393.27	-56.60	-87.30	-35.17
Equity	184.60	184.50	0.05	184.60	184.50	0.05	184.60	184.50	0.05
PBIDTM(%)	11.41	5.17	120.62	11.41	5.17	120.62	11.08	9.65	14.79

Jul, 2026

Alembic Pharma moves up on getting USFDA’s final approval for Prucalopride Tablets

Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults

Jul, 2026

Alembic Pharma gets USFDA’s final approval for Prucalopride Tablets

Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults

Jul, 2026

Indoco Remedies informs about change in management

Indoco Remedies has informed that the Board of Directors in its Meeting held today i.e. 28th July, 2026 has considered and approved Re-appointment of Aditi Panandikar as the Managing Director of the Company for the period of 5 years commencing from 15th February, 2027 to 14th February, 2032, subject to the approval of the shareholders in the ensuing AGM; and appointment of Sudhir Kadam as Senior Management Personnel designated as Sr. Vice President (Human Capital) of the Company with effect from 28th July, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	199 Crore
2	Health X Platform Ltd.	968 Crore
3	Indoco Remedies Ltd.	2,105 Crore
4	Unichem Laboratories Ltd.	3,763 Crore
5	Solara Active Pharma Sciences Ltd.	2,446 Crore
6	Suraksha Diagnostic Ltd.	1,297 Crore
7	Jubilant Pharmova Ltd.	15,366 Crore
8	Dishman Carbogen Amcis Ltd.	2,857 Crore
9	Biocon Ltd.	70,452 Crore
10	Shilpa Medicare Ltd.	11,839 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,740	59,301	38.21	12.49	26.17	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,881	1,86,354	86.14	22.16	44.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,458	1,09,494	20.53	4.89	11.88	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,377	41,675	39.47	9.21	26.67	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,657	67,559	30.92	4.83	22.42	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,780	94,987	97.82
Sai Life Sciences Ltd. (S)	Very Good	1,311	27,605	57.56
Aurobindo Pharma Ltd. (M)	Very Good	1,592	89,212	37.52
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,881	1,86,354	35.15
Lupin Ltd. (M)	Somewhat Good	2,458	1,09,494	22.15
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,311	27,605	80.84	11.01	42.51	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,377	41,675	39.47	9.21	26.67	13.54
Mankind Pharma Ltd. (M)	Very Good	2,607	1,08,129	53.07	6.61	33.20	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,127	1,09,686	21.76	4.22	13.36	13.52
Lupin Ltd. (M)	Somewhat Good	2,458	1,09,494	20.53	4.89	11.88	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,458	1,09,494	20.53	4.89	11.88	32.37
Abbott India Ltd. (M)	Very Good	27,740	59,301	38.21	12.49	26.17	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,145	94,790	29.42	2.48	15.11	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,127	1,09,686	21.76	4.22	13.36	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,985	4,74,397	41.33	5.68	23.70	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Biocon informs about company statement

Indoco Remedies - Quaterly Results

Alembic Pharma moves up on getting USFDA’s final approval for Prucalopride Tablets

Alembic Pharma gets USFDA’s final approval for Prucalopride Tablets

Indoco Remedies informs about change in management

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.